Ted White - 24 Feb 2022 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
President and CEO, Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
VRCA
Transactions as of
24 Feb 2022
Net transactions value
$0
Form type
4
Filing time
25 Feb 2022, 15:30:45 UTC
Previous filing
07 Jun 2021
Next filing
21 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRCA Employee Stock Option (right to buy) Award $0 +200,000 $0.000000 200,000 24 Feb 2022 Common Stock 200,000 $8.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the total shares subject to the option shall vest on February 24, 2023 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.